Privia Health Group, Inc. Stock Price, News & Analysis

On February 14, 2022, Javara announced a clinical trial for an investigational vaccine, mRNA-1345, aimed at preventing respiratory syncytial virus (RSV) in adults aged 60 and older. This trial, conducted in partnership with Privia Health and Moderna (Nasdaq: MRNA), will enroll approximately 34,000 participants across Fayetteville, Annapolis, and Fort Worth. RSV causes significant health issues, with over 177,000 hospitalizations yearly among older adults in the U.S. The trial aims to evaluate the vaccine's safety and efficacy, addressing the urgent need for preventive measures against RSV.

Privia Health Group, Inc. (Nasdaq: PRVA) and Surgery Partners, Inc. (Nasdaq: SGRY) announced a strategic partnership to enhance healthcare delivery in Montana. This agreement grants Privia access to the Great Falls Clinic, a multi-specialty practice with 65 providers, serving as a base for building a statewide network.

Privia Health will also manage the newly established Privia Management Company of Montana, focusing on clinical operations and performance services. The partnership aims to improve patient care while expanding both companies' operational capacities in Montana.

ARLINGTON, Va., Jan. 31, 2022 - Privia Health Group, Inc. (Nasdaq: PRVA) will release its fourth quarter and full year financial results for 2021 on March 25, 2022, before the market opens. The press release will be available at ir.priviahealth.com by 7:00 AM ET. Following this, the management will hold a conference call at 8:00 AM ET to discuss the results and future outlook. Interested parties can access the call via a webcast or by phone. The recording will be available for replay shortly after the call.

Privia Health Group, Inc. (Nasdaq: PRVA) has launched three new Accountable Care Organizations (ACOs) in Maryland, Florida, and Tennessee, bringing the total to seven ACOs in its portfolio. Effective January 1, 2022, the Privia Quality Network now includes over 1,900 independent providers serving 168,000+ Medicare beneficiaries. Four ACOs have transitioned to the MSSP Enhanced Track, which entails significant financial risks. In 2020, Privia achieved $86.5 million in shared savings through MSSP, with total savings exceeding $576 million since 2014.

Privia Health Group, Inc. (Nasdaq: PRVA) has appointed Jeffrey S. Sherman as Executive Vice President and Chief Financial Officer, effective immediately. Sherman, who brings significant financial and healthcare experience from previous roles, will oversee finance and accounting activities. Privia Health CEO Shawn Morris emphasized that Sherman’s background will support the company’s growth and long-term value creation. Sherman succeeds David Mountcastle, who is leaving the company after a successful tenure. Privia Health focuses on optimizing physician practices and enhancing patient experiences.

Privia Health Group, Inc. (Nasdaq: PRVA) has announced new capitated arrangements with HealthFirst Health Plan and Humana for its Accountable Care Organizations (ACOs) in Florida and the Mid-Atlantic region. Effective January 1, 2022, these agreements will provide healthcare services to approximately 23,000 Medicare Advantage beneficiaries. The company expects to generate $230 million in practice collections and GAAP revenue from these contracts in 2022, marking a shift from fee-for-service to care management fees for enhanced healthcare services.

ARLINGTON, Va., Jan. 04, 2022 – Privia Health Group, Inc. (Nasdaq: PRVA) will participate in the 40th Annual J.P. Morgan Healthcare Conference. The management team is scheduled to present a business overview during a virtual fireside chat on January 10, 2022, at 3:00 PM ET. A webcast, replay, and accompanying slide presentation will be available on their investor relations website.

Privia Health is a technology-driven physician enablement company that collaborates with medical groups and health systems to optimize practices, improve patient experiences, and enhance healthcare quality.

Privia Health Group, Inc. (Nasdaq: PRVA) has priced its public offering of 6,000,000 shares of common stock at $29.00 per share. The offering, initiated by selling stockholders, includes a 30-day option for underwriters to purchase an additional 900,000 shares. The company will not receive any proceeds from this secondary offering, which is set to close on November 23, 2021. The offering is managed by leading financial institutions including Goldman Sachs and J.P. Morgan. Forward-looking statements highlight potential uncertainties regarding the completion of the offering.

Privia Health Group, Inc. (Nasdaq: PRVA) announced a public offering of 6,000,000 shares of common stock by certain selling stockholders, with a 30-day option for underwriters to purchase an additional 900,000 shares. The company will not receive any proceeds from this offering, as costs will be borne by the selling stockholders. Goldman Sachs & Co. LLC and J.P. Morgan are leading the offering. A registration statement has been filed but is not yet effective, and the offering is subject to numerous conditions outside Privia's control.